## Justin A Mariani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6837402/publications.pdf Version: 2024-02-01



LUCTIN & MADIANI

#	Article	IF	CITATIONS
1	Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction. Journal of the American College of Cardiology, 2017, 70, 1949-1961.	2.8	428
2	Cardiac Complications of Thoracic Irradiation. Journal of the American College of Cardiology, 2013, 61, 2319-2328.	2.8	310
3	Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Therapy, 2008, 15, 1550-1557.	4.5	157
4	The transcardiac gradient of cardioâ€ <scp>microRNAs</scp> in the failing heart. European Journal of Heart Failure, 2016, 18, 1000-1008.	7.1	151
5	Percutaneous Cardiac Recirculation-Mediated Gene Transfer of an Inhibitory Phospholamban Peptide Reverses Advanced Heart Failure in Large Animals. Journal of the American College of Cardiology, 2007, 50, 253-260.	2.8	136
6	Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 495-505.	7.1	108
7	Sympathetic Neural Adaptation to Hypocaloric Diet With or Without Exercise Training in Obese Metabolic Syndrome Subjects. Diabetes, 2010, 59, 71-79.	0.6	104
8	Tolerance to ischemia and hypoxia is reduced in aged human myocardium. Journal of Thoracic and Cardiovascular Surgery, 2000, 120, 660-667.	0.8	103
9	Bone Marrow-Derived Cells Contribute to Fibrosis in the Chronically Failing Heart. American Journal of Pathology, 2010, 176, 1735-1742.	3.8	94
10	Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. Journal of Hypertension, 2011, 29, 553-564.	0.5	93
11	Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. American Journal of Clinical Nutrition, 2009, 89, 27-36.	4.7	90
12	Sex Differences in Heart Failure WithÂPreserved Ejection FractionÂPathophysiology. JACC: Heart Failure, 2019, 7, 239-249.	4.1	82
13	Hemodynamic Determinants of Myocardial B-Type Natriuretic Peptide Release. Hypertension, 2010, 56, 682-689.	2.7	64
14	Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2016, 27, 571-580.	1.7	56
15	Augmentation of left ventricular mechanics by recirculationâ€mediated AAV2/1–SERCA2a gene delivery in experimental heart failure. European Journal of Heart Failure, 2011, 13, 247-253.	7.1	51
16	Coenzyme Q <sub>10</sub> improves the tolerance of the senescent myocardium to aerobic and ischemic stress: Studies in rats and in human atrial tissue. BioFactors, 1999, 9, 291-299.	5.4	50
17	Impaired Myocardial Oxygen Availability Contributes to Abnormal Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2014, 3, e001293.	3.7	47
18	A prospective <scp>STudy</scp> using <scp>invAsive</scp> haemodynamic measurements <scp>foLLowing</scp> catheter ablation for <scp>AF</scp> and early <scp>HFpEF</scp> : <scp>STALL AFâ€HFpEF</scp> . European Journal of Heart Failure, 2021, 23, 785-796.	7.1	43

#	Article	IF	CITATIONS
19	Evaluating the Utility of Circulating Biomarkers of Collagen Synthesis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2014, 7, 271-278.	3.9	42
20	Regression of Diffuse Ventricular FibrosisÂFollowing Restoration of SinusÂRhythm With Catheter Ablation inÂPatients With Atrial Fibrillation andÂSystolic Dysfunction. JACC: Clinical Electrophysiology, 2018, 4, 999-1007.	3.2	39
21	Coadministration of Atorvastatin Prevents Nitroglycerin-Induced Endothelial Dysfunction and Nitrate Tolerance in Healthy Humans. Journal of the American College of Cardiology, 2011, 57, 93-98.	2.8	32
22	The successful treatment of primary cardiac lymphoma with a dose-dense schedule of rituximab plus CHOP. Annals of Oncology, 2006, 17, 176-177.	1.2	30
23	Utility of Myocardial Fibrosis and Fatty Infiltration Detected by Cardiac Magnetic Resonance Imaging in the Diagnosis of Arrhythmogenic Right Ventricular Dysplasia—A Single Centre Experience. Heart Lung and Circulation, 2008, 17, 478-483.	0.4	30
24	Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. International Journal of Cardiology, 2015, 187, 227-228.	1.7	30
25	Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H939-H945.	3.2	29
26	Effects of Milrinone on Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 67, 2554-2556.	2.8	28
27	Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure. European Journal of Heart Failure, 2013, 15, 292-298.	7.1	27
28	Prevalence of tricuspid regurgitation and pericardial effusions following pacemaker and defibrillator lead extraction. International Journal of Cardiology, 2010, 145, 593-594.	1.7	26
29	The Impact of Known Heart Disease on Longâ€Term Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction: A Multicenter International Study. Journal of Cardiovascular Electrophysiology, 2016, 27, 281-289.	1.7	25
30	Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia During the COVID-19 Pandemic: A Living Document. Heart Lung and Circulation, 2020, 29, e57-e68.	0.4	25
31	Rural and Remote Cardiology During the COVID-19 Pandemic: Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement. Heart Lung and Circulation, 2020, 29, e88-e93.	0.4	25
32	Miniaturized implantable cardiac monitor with a long sensing vector (BIOMONITOR III): Insertion procedure assessment, sensing performance, and home monitoring transmission success. Journal of Electrocardiology, 2020, 60, 118-125.	0.9	23
33	Exercise with a Twist: Left Ventricular Twist and Recoil in Healthy Young and Middle-Aged Men, and Middle-Aged Endurance-Trained Men. Journal of the American Society of Echocardiography, 2012, 25, 986-993.	2.8	22
34	A comparison of the electrophysiologic and electroanatomic characteristics between the right and left atrium in persistent atrial fibrillation: Is the right atrium a window into the left?. Journal of Cardiovascular Electrophysiology, 2017, 28, 1109-1116.	1.7	22
35	Intraoperative High-Density Global Mapping in Adult-Repaired Tetralogy of Fallot. Journal of the American College of Cardiology, 2010, 55, 2409-2411.	2.8	21
36	Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment NaĀ־ve Type 2 Diabetes following Equivalent Weight Loss. Frontiers in Physiology, 2016, 7, 516.	2.8	20

#	Article	IF	CITATIONS
37	Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients. JACC Basic To Translational Science, 2022, 7, 116-127.	4.1	20
38	Biatrial Electrical and Structural AtrialÂChanges in Heart Failure. JACC: Clinical Electrophysiology, 2018, 4, 87-96.	3.2	18
39	Aortic Valve Replacement for Aortic Stenosis During Orthotopic Cardiac Transplant. Annals of Thoracic Surgery, 2008, 86, 1979-1982.	1.3	16
40	Implantable cardioverter defibrillator knowledge and end-of-life device deactivation: A cross-sectional survey. Palliative Medicine, 2018, 32, 156-163.	3.1	14
41	Reduction in peripheral vascular resistance predicts improvement in insulin clearance following weight loss. Cardiovascular Diabetology, 2015, 14, 113.	6.8	13
42	Clinical utility of invasive exercise hemodynamic evaluation in LVAD patients. Journal of Heart and Lung Transplantation, 2015, 34, 1635-1637.	0.6	13
43	Hemodynamic Profile of Patients With Heart Failure and Preserved Ejection Fraction Vary by Age. Journal of the American Heart Association, 2017, 6, .	3.7	13
44	Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology. Journal of the American Heart Association, 2021, 10, e021584.	3.7	12
45	Delivery of Gene and Cellular Therapies for Heart Disease. Journal of Cardiovascular Translational Research, 2010, 3, 417-426.	2.4	11
46	A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies. Cancers, 2019, 11, 1046.	3.7	11
47	Left Ventricular Ejection Fraction and Absence of ACE Inhibitor/Angiotensin II Receptor Blocker Predicts Appropriate Defibrillator Therapy in the Primary Prevention Population. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 696-704.	1.2	10
48	Determinants and implications of elevated soluble ST2 levels in heart failure. International Journal of Cardiology, 2014, 176, 1242-1243.	1.7	9
49	Identification of physiologic treatment targets with favourable haemodynamic consequences in heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 3685-3693.	3.1	9
50	Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 992-998.	1.2	8
51	Outcomes of anemic patients presenting with acute coronary syndrome: An analysis of the Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events. Clinical Cardiology, 2019, 42, 791-796.	1.8	8
52	Severe left ventricular hypertrophy and marked cardiac fibrosis in Danon disease. International Journal of Cardiology, 2016, 221, 14-16.	1.7	7
53	Determining the Optimal Dose of Adenosine for Unmasking Dormant Pulmonary Vein Conduction Following Atrial Fibrillation Ablation: Electrophysiological and Hemodynamic Assessment. DORMANTâ€AF Study. Journal of Cardiovascular Electrophysiology, 2017, 28, 13-22.	1.7	7
54	Impact of device length on electrogram sensing in miniaturized insertable cardiac monitors. Journal of Electrocardiology, 2022, 73, 42-48.	0.9	7

4

#	Article	IF	CITATIONS
55	Cardiac resynchronization therapy after atrioventricular node ablation for rapid atrial fibrillation in a heart transplant recipient with late allograft dysfunction. Journal of Heart and Lung Transplantation, 2010, 29, 704-706.	0.6	6
56	Trends in outpatient antiâ€arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997–2016. Internal Medicine Journal, 2018, 48, 427-432.	0.8	6
57	Absence of late gadolinium enhancement on cardiac magnetic resonance imaging in ventricular fibrillation and nonischemic cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1109-1115.	1.2	6
58	Increased Incidence of Noise in the Tendril Pacemaker Lead Detected via Remote Monitoring. Heart Lung and Circulation, 2020, 29, 936-939.	0.4	6
59	Restoration of blood pressure control with pacemaker implantation in a patient with bradycardia and resistant hypertension: A case report. International Journal of Cardiology, 2013, 167, e38-e40.	1.7	5
60	Clinical benefits of a specialised clinic for hypertrophic cardiomyopathy. Internal Medicine Journal, 2015, 45, 255-260.	0.8	5
61	Retained defibrillator leads following orthotopic heart transplantation. International Journal of Cardiology, 2016, 215, 87-89.	1.7	5
62	Caudal fluoroscopy to guide venous access for pacemaker device implantation: should this now be standard practice?. Heart Asia, 2017, 9, 68-69.	1.1	5
63	Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature. Internal Medicine Journal, 2022, 52, 841-847.	0.8	5
64	Cardiac resynchronisation therapy for heart failure. Internal Medicine Journal, 2006, 36, 114-123.	0.8	4
65	Primary Cardiac Lymphoma. Journal of the American College of Cardiology, 2010, 55, e23.	2.8	4
66	Cardiac implantable electronic device hematomas: Risk factors and effect of prophylactic pressure bandaging. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 857-867.	1.2	4
67	Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management. Cardiovascular Drugs and Therapy, 2018, 32, 37-46.	2.6	4
68	Impact of Individual Patient Profiles on Adherence to Guideline Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: VCOR-HF Study. Heart Lung and Circulation, 2020, 29, 1782-1789.	0.4	4
69	Norepinephrine transporter expression is inversely associated with glycaemic indices: a pilot study in metabolically diverse persons with overweight and obesity. Obesity Science and Practice, 2016, 2, 13-23.	1.9	3
70	Cardiac Implantable Electronic Devices and End-of-Life Care: An Australian Perspective. Heart Lung and Circulation, 2016, 25, 814-819.	0.4	3
71	The effect of parity on exercise physiology in women with heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 214-223.	3.1	3
72	Prediction of Pacemaker Requirement in Patients With Unexplained Syncope: The DROP Score. Heart Lung and Circulation, 2022, 31, 999-1005.	0.4	3

#	Article	IF	CITATIONS
73	Biventricular pacing in heart failure: a review. Expert Review of Cardiovascular Therapy, 2006, 4, 97-109.	1.5	2
74	Asystole Following Complex Partial Seizures. Heart Lung and Circulation, 2013, 22, 146-148.	0.4	2
75	An overlooked case of pacemaker-related heart failure. Journal of Animal Science and Technology, 2017, 4, K57-K60.	2.5	2
76	Age-related decline in stress responses of human myocardium may not be explained by changes in mtDNA. Mechanisms of Ageing and Development, 2009, 130, 742-747.	4.6	1
77	Cardiac resynchronisation therapy in 2015: keeping up with the pace. Internal Medicine Journal, 2016, 46, 255-265.	0.8	1
78	SEX DIFFERENCES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: AN INVASIVE HEMODYNAMIC ANALYSIS. Journal of the American College of Cardiology, 2019, 73, 921.	2.8	1
79	The prognostic significance of chronotropic incompetence in patients with severe left ventricular systolic function referred for cardiac transplant assessment. European Journal of Preventive Cardiology, 2020, 27, 328-330.	1.8	1
80	Non-invasive blood pressure monitoring underestimates hypertensive response to exercise in suspected heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2020, 27, 2180-2182.	1.8	1
81	Response of the Human Myocardium to Hypoxia and Ischemia Declines with Age: Correlation with Increased Mitochondrial DNA Deletions. Annals of the New York Academy of Sciences, 1998, 854, 489-490.	3.8	Ο
82	Repair Of postmyocardial infarct ventricular free wall rupture using an onlay pericardial patch. Heart, Lung and Circulation, 1999, 8, 110-114.	0.1	0
83	Progression of Functional Mitral Regurgitation in Heart Failure Is Associated with Structural Remodeling and Worsened Outcomes. Journal of Cardiac Failure, 2008, 14, S32.	1.7	Ο
84	Myocardial Release of Stromal Derived Factor-1 and Stem Cell Factor and Cardiac Uptake of Progenitor Cells. Journal of Cardiac Failure, 2008, 14, S33.	1.7	0
85	Cardiac-Resynchronization Therapy. New England Journal of Medicine, 2010, 362, 177-179.	27.0	0
86	Successful application of a PressureWire retrogradely across an ATS prosthetic aortic valve to diagnose constrictive pericarditis. Cardiovascular Revascularization Medicine, 2012, 13, 289-291.	0.8	0
87	Left Ventricular Assist Device (LVAD) as a Bridge to Recovery for Tachycardia-Mediated Cardiomyopathy. Journal of Cardiac Surgery, 2015, 30, 871-873.	0.7	0
88	Driving with cardiac devices in Australia. Does a review of recent evidence prompt a change in guidelines?. Internal Medicine Journal, 2020, 50, 271-277.	0.8	0
89	Contemporary trends in antiplatelet prescription in Australia. Journal of Pharmacy Practice and Research, 2020, 50, 366-368.	0.8	0
90	Physiologic Insights Into Long COVID Breathlessness. Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121009346.	3.9	0